Pernix Therapeutics Holdings buy rating reiterated at Brean Capital. $3.00 PT. 7/10/2016
http://www.marketbeat.com/r/670976 $PTX #PTX vía @RatingsNetwork
06/29/2016 | 12:40am EDT
Pharmaceutical company Pernix Therapeutics Holdings Inc announced positive final results from a Phase IV Study assessing the effects of nighttime administration of insomnia treatments, Silenor 6 mg and zolpidem 10 mg, as well as placebo, on arousability, gait, balance, and cognitive performance, after going to sleep, in healthy male volunteers. These data were presented at the SLEEP 2016 meeting.
The study assessed the effects of a single dose of Silenor 6 mg compared with matching placebo and a single dose of zolpidem 10 mg compared to its matching placebo at the respective Tmax (time the maximum serum concentrations are observed) in normal healthy adult male volunteers (n=52). The results of the study demonstrated that Silenor 6 mg was statistically superior to zolpidem 10 mg on the measures studied—arousability, gait, balance, and memory.
John Sedor, Pernix Therapeutics chairman and CEO, says in a release: “The results of this head-to-head study further support certain key benefits of Silenor 6 mg. Pernix is encouraged by these data and the impact they could have on the sleep community and patients.”
The results also indicated that subjects taking Silenor 6 mg did not have impairment on arousability, gait, balance, and cognitive performance, and were comparable to placebo. Further, in addition to Silenor 6 mg, both placebo groups were also statistically superior to zolpidem on the measures evaluated, indicating that zolpidem subjects had statistically significant difficulty in waking up, with walking and balance and with memory. Finally, there were no differences in efficacy measures between zolpidem 10 mg and Silenor 6 mg, while several measures were significantly improved with Silenor 6 mg versus placebo.
June 29, 2016
by Dannica Stinson
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX)has revealed that its accounts payable, for the year ended 2016-03-31, stands at $37.406 million. The company also provided an update on the accounts payable for the quarter ended 2016-03-31, which amount to $37.406 million. As such, the change in accounts payable for the full year ended 2016-03-31 and quarter ended 2016-03-31 stood at $6.682 million and $6.682 million, respectively.
In addition to this, the company’s deferred tax assets were $6.544 million, for the full year ended 2016-03-31. The figure for the deferred tax assets was $6.544 million, for the quarter ended 2016-03-31.
The company’s asset and liabilities account registered a change of -0.211 millions, for the full year ended 2016-03-31, while a change of $-0.211 million was observed for the quarter ended 2016-03-31.
For the full year ended 2016-03-31, the days sales in receivables stood at 141.0268. The days sales in receivables represents the average number of days it takes for the company to collected the receivables owed by customers. The figure was 141.0268 for the quarterly period ended 2016-03-31.
Furthermore, the accounts receivables for Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) registered a movement of $-17.082 million and $-17.082 million, for the full year and quarterly periods, ended 2016-03-31 and 2016-03-31, respectively.
The company’s inventory for the full year ended 2016-03-31 was $0.444 million. Moreover, the figure for the quarter ended 2016-03-31 was $0.444 million.
Outstanding debt was 7.345 million and $7.345 million for the full year ended 2016-03-31 and quarterly period ended 2016-03-31, respectively.
Form 4 ¿¿??
An average of $ 180 million sales a year. ;)
Sentiment: Strong Buy
Top 10 Owners of Pernix Therapeutics Holdings Inc
Broadfin Capital LLC 9.53% 6,090,829 4,568,122 0 0.00%
Morgan Stanley & Co. LLC 8.22% 5,252,893 3,939,670 +98,250 +1.91%
venBio Select Advisor LLC 6.09% 3,889,900 2,917,425 -1,255,016 -24.39%
Point72 Asset Management LP 5.83% 3,724,344 2,793,258 +1,224,344 +48.97%
Stonepine Capital Management LLC 5.03% 3,215,861 2,411,896 +731,212 +29.43%
BlackRock Fund Advisors 4.12% 2,634,407 1,975,805 +162,369 +6.57%
Elk Creek Partners LLC 3.61% 2,308,946 1,731,710 +55,279 +2.45%
The Vanguard Group, Inc. 2.81% 1,796,619 1,347,464 +6,513 +0.36%
Athyrium Capital Management LLC 1.89% 1,205,036 903,777 -2,583,966 -68.20%
OrbiMed Advisors LLC 1.68% 1,073,000 804,7